Myeloid Leukemia

Index 305
BCR–ABL fusion detection in
chronic myeloid leukemia, see
BCR–ABL fusion
cDNA synthesis, 9–11, 76, 77, 120,
122, 123, 181
FIP1L1–PDGFRA fusion detection,
see FIP1L1–PDGFRA fusion
principles, 27, 28
PRV1 overexpression, see Essential
thrombocythemia;
Polycythemia vera
real-time quantitative polymerase
chain reaction for acute
myeloid leukemia, see also
AML1–ETO fusion; CBFB–
MYH11 fusion; PML–RARA
fusion,
acute myeloid leukemia fusion
gene detection,
EAC protocol, 50, 51
primers, 49
double-stranded DNA detection,
Amplifluor hairpin primers, 33
DNAzyme, 35, 36
light-up probe, 33
SybrGreen I, 31, 32
instrumentation, 43–46
interpretation in absolute
quantification, 58–61
minimal residual disease
detection, 28, 60–62
normalization, 53, 54
preparation of run, 48, 50
primer and probe design, 46–48
principles, 30
prospects, 63
quality control, 51–53, 62, 63
quantification,
absolute, 54, 55
relative, 55, 56
reporting, 56–58
specific fragment detection,
hybridization probes, 39
locked nucleic acid, 38, 39
minor groove binder, 37, 38
Molecular Beacon, 39
Scorpion probe, 40, 41, 43
TaqMan assay, 37
RNA isolation, see RNA isolation
WT1 overexpression, see WT1
RNA extraction,
AML1–ETO fusion transcripts, 150,
151, 160
anticoagulants, 4, 10
approaches, 5
BCR–ABL fusion detection,
cDNA synthesis, 76, 77
extraction, 75, 76
materials, 72, 73
commercial kits, 5, 6, 11
DNA microarray analysis of acute
myeloid leukemia, 215, 217,
237
gel electrophoresis analysis, 7
guanidium thiocyanate lysis and
cesium chloride
ultracentrifugation, 6, 7, 11
PML–RARA fusion detection, 134,
135, 144
PRV1 transcripts, 267, 268
ribonuclease avoidance, 5, 10, 11
WT1 transcripts, 203, 209
RT-PCR, see Reverse transcriptionpolymerase
chain reaction
S
SAM, see Significance analysis of
microarrays
Scorpion probe, fragment detection in
real-time quantitative
polymerase chain reaction, 40,
41, 43
Significance analysis of microarrays
(SAM), principles, 228